What is Eligo Bioscience?
Eligo Bioscience is a pioneering biotechnology firm specializing in the development of in vivo gene editing technologies designed to modulate the human microbiome. At the core of its operations is the GEM (Gene Editing of the Microbiome) platform, a sophisticated toolset that enables the precise modification of bacterial gene repertoires. By targeting the root causes of diseases with high unmet medical needs, Eligo is effectively redefining the therapeutic landscape for microbiome-associated conditions. The company's market position is bolstered by a leadership team of renowned scientists and a strategic focus on high-impact, precision-based interventions that differentiate it from traditional pharmaceutical approaches.
How much funding has Eligo Bioscience raised?
Eligo Bioscience has raised a total of $55M across 3 funding rounds:
Series A
$20M
Series B
$30M
Grant
$5M
Series A (2017): $20M with participation from Khosla Ventures and Seventure Partners
Series B (2023): $30M led by Bpifrance, Sanofi Ventures, Khosla Ventures, and Seventure Partners
Grant (2025): $5M supported by Ministry for Europe and Foreign Affairs
Key Investors in Eligo Bioscience
Khosla Ventures
A prominent venture capital firm providing strategic guidance and capital to entrepreneurs developing breakthrough technologies across sectors including health, AI, and sustainable energy.
Seventure Partners
An active investment partner specializing in life sciences and digital technologies, with a strong focus on innovative startups addressing health, nutrition, and environmental challenges.
Sanofi Ventures
The corporate venture capital arm of Sanofi, focusing on early-stage biotech and digital health companies that align with their strategic interests in oncology, immunology, and rare diseases.
What's next for Eligo Bioscience?
With the recent influx of capital, Eligo Bioscience is well-positioned to transition its lead candidates into advanced clinical trials, further validating the efficacy of its GEM platform. The strategic focus will likely shift toward expanding its therapeutic portfolio and strengthening its intellectual property moat in the competitive gene-editing space. As the company scales, it will continue to leverage its partnerships with major venture firms and government entities to navigate regulatory hurdles and optimize its manufacturing processes. The integration of these resources will be critical as Eligo seeks to transform its innovative research into scalable, commercial-ready solutions for patients suffering from chronic, microbiome-linked diseases.
See full Eligo Bioscience company page
